Advances in artificial intelligence for meibomian gland evaluation: A comprehensive review.

Journal: Survey of ophthalmology
PMID:

Abstract

Meibomian gland dysfunction (MGD) is increasingly recognized as a critical contributor to evaporative dry eye, significantly impacting visual quality. With a global prevalence estimated at 35.8 %, it presents substantial challenges for clinicians. Conventional manual evaluation techniques for MGD face limitations characterized by inefficiencies, high subjectivity, limited big data processing capabilities, and a dearth of quantitative analytical tools. With rapidly advancing artificial intelligence (AI) techniques revolutionizing ophthalmology, studies are now leveraging sophisticated AI methodologies--including computer vision, unsupervised learning, and supervised learning--to facilitate comprehensive analyses of meibomian gland (MG) evaluations. These evaluations employ various techniques, including slit lamp examination, infrared imaging, confocal microscopy, and optical coherence tomography. This paradigm shift promises enhanced accuracy and consistency in disease evaluation and severity classification. While AI has achieved preliminary strides in meibomian gland evaluation, ongoing advancements in system development and clinical validation are imperative. We review the evolution of MG evaluation, juxtapose AI-driven methods with traditional approaches, elucidate the specific roles of diverse AI technologies, and explore their practical applications using various evaluation techniques. Moreover, we delve into critical considerations for the clinical deployment of AI technologies and envisages future prospects, providing novel insights into MG evaluation and fostering technological and clinical progress in this arena.

Authors

  • Li Li
    Department of Gastric Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
  • Kunhong Xiao
    Department of Optometry, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China.
  • Xianwen Shang
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
  • Wenyi Hu
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
  • Mayinuer Yusufu
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia; Department of Surgery (Ophthalmology), The University of Melbourne, Melbourne, Australia.
  • Ruiye Chen
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
  • Yujie Wang
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia.
  • Jiahao Liu
    School of Artificial Intelligence, Hebei University of Technology, Tianjin, 300130, China.
  • Taichen Lai
    Department of Clinical Medicine, Fujian Medical University, Fuzhou, China.
  • Linling Guo
    Department of Clinical Medicine, Fujian Medical University, Fuzhou, China.
  • Jing Zou
    School of Accounting, Wuhan College, Wuhan 430212, Hubei, China.
  • Peter van Wijngaarden
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, VIC.
  • Zongyuan Ge
    AIM for Health Lab, Faculty of IT, Monash University, Clayton, Victoria, Australia; Monash-Airdoc Research Lab, Faculty of IT, Monash University, Clayton, Victoria, Australia.
  • Mingguang He
    State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China; Centre for Eye Research Australia; Departments of Ophthalmology and Surgery, University of Melbourne, Melbourne, Australia. Electronic address: mingguang.he@unimelb.edu.au.
  • Zhuoting Zhu
    Department of Ophthalmology, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Guangzhou, China.